Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Pathologic Characteristics of Spitz Melanoma With MAP3K8 Fusion or Truncation in a Pediatric Cohort

Newman, Scott PhD*; Pappo, Alberto MD; Raimondi, Susana PhD; Zhang, Jinghui PhD*; Barnhill, Raymond MD§; Bahrami, Armita MD†,‡

The American Journal of Surgical Pathology: September 06, 2019 - Volume Publish Ahead of Print - Issue - p
doi: 10.1097/PAS.0000000000001362
Original Article: PDF Only
Buy
PAP

Spitz melanoma is a rare variant of melanoma defined by distinct clinical, histologic, and genetic features and affecting patients of all ages. Half of these tumors are driven by fusion of kinase genes including ALK, NTRK1/3, ROS1, RET, MET, or BRAF. We recently reported recurrent fusion or truncation of the potentially targetable serine-threonine kinase gene MAP3K8 in 33% of Spitz melanomas. Here we describe the histologic features of these MAP3K8-rearranged tumors (16 pediatric Spitz melanomas; 1 atypical Spitz tumor), using hematoxylin-eosin slides, p16 immunohistochemistry, and CDKN2A fluorescence in situ hybridization. The lesions consisted of a compound melanocytic proliferation, ranging in thickness from 1.5 to 13.4 mm (median, 3.1 mm), with 8 having a predominant dermal and 3 having a predominant junctional component. The predominant cell type was epithelioid (94%). The epithelioid melanocytes were generally monomorphic and amelanotic, arranged in expansile epithelial aggregates, confluent hypercellular nests, or enlarged syncytial nodules in the dermis. Ulceration was present in 9 of 17 tumors (53%) and deep mitotic figures were seen in 15 of 17 tumors (88%). Complete loss of p16 expression and homozygous CDKN2A deletion were observed in 82% and 70% of tumors, respectively. Recognition of MAP3K8-altered Spitz melanoma may thus be facilitated by these morphologic features, most notably presence of cohesive cellular nodules in the dermis and an epithelioid-cell phenotype.

Departments of *Computational Biology

Oncology

Pathology, St. Jude Children’s Research Hospital, Memphis, TN

§Departments of Pathology and Translational Research, Institut Curie, Paris, France

Conflicts of Interest and Source of Funding: Supported in part by ALSAC. The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Correspondence: Armita Bahrami, MD, Department of Pathology, St. Jude Children’s Research Hospital, 262 Danny Thomas Place, MS 250, Memphis, TN 38105 (e-mail: armita.bahrami@stjude.org).

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.